Page last updated: 2024-09-03

tafenoquine and Plasmodium vivax Malaria

tafenoquine has been researched along with Plasmodium vivax Malaria in 60 studies

Research

Studies (60)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (3.33)	18.2507
2000's	11 (18.33)	29.6817
2010's	29 (48.33)	24.3611
2020's	18 (30.00)	2.80

Authors

Authors	Studies
Breton, JJ; Chau, NH; Duparc, S; Ernest, TB; Goyal, N; Green, JA; Hien, TT; Hoa, NT; Jones, SW; Martin, A; Mohamed, K; Rolfe, K; Rousell, VM; Sharma, H; Tan, LK; Taylor, M; Vélez, ID	1
Herrera, S; Hsiang, MS; Llanos-Cuentas, A; Manrrique, P; Rosas-Aguirre, A	1
Nekkab, N; Watson, JA; White, M	1
Gautam, CS; Sharma, J; Singh, H; Singh, J	1
Choi, JY; Kim, C; Kim, JD; Kim, JH; Lee, J; Suh, J; Yeom, JS	1
Baird, JK; Berni, A; Budiman, W; Cedar, E; Chand, K; Crenna-Darusallam, C; Duparc, S; Ekawati, LL; Elyazar, I; Fernando, D; Fletcher, K; Goyal, N; Green, JA; Instiaty, I; Jones, S; Kleim, JP; Lardo, S; Martin, A; Noviyanti, R; Prasetya, CB; Rolfe, K; Santy, YW; Satyagraha, AW; Sharma, H; Soebandrio, A; Subekti, D; Sutanto, I; Tan, LK; Taylor, M	1
Commons, RJ; Thriemer, K	1
Markus, MB	1
Janković, SM; Kostić, M; Milosavljević, MN; Ranković, G; Stefanović, S	1
Awab, GR; Contantia, F; Day, NP; Devine, A; Gilchrist, K; Green, JA; Hailu, A; Koh, GC; Lubell, Y; Ngo, VT; Nguyen, TN; Pasaribu, AP; Pham, HT; Price, RN; Taylor, WR; Teferi, T; Thriemer, K; Tran, TH	1
Derbyshire, ER; Lu, KY	1
Chalon, S; Duparc, S; Miller, S; Richardson, N; Toovey, S	1
Devine, A; Dittrich, S; Howes, RE; Ley, B; Moore, KA; Price, DJ; Price, RN; Simpson, JA	1
Breton, JJ; Duparc, S; Espino, FEJ; Green, JA; Hien, TT; Koh, GCKW; Krudsood, S; Lacerda, MVG; Llanos-Cuentas, A; Lon, C; Mohammed, R; Namaik-Larp, CS; Pereira, DB; Saunders, DL; St Jean, PL; Velez, ID; Villegas, MF; Yilma, D	1
Sayers, DR; Webber, BJ	1
Fernando, D; Rajapakse, S; Rodrigo, C	2
Chu, CS; Hwang, J	1
Contreras-Mancilla, J; Delgado-Ratto, C; Fernandez-Miñope, C; Ferrucci, HR; Gamboa, D; Llanos-Cuentas, A; Van Geertruyden, JP	1
Ahmad, SS; Rahi, M; Sharma, A	1
Lacerda, M; Lana, R; Monteiro, W; Mueller, I; Nekkab, N; Obadia, T; Siqueira, A; Villela, D; White, M	1
Dow, G; Smith, B	1
Buathong, N; Euswas, A; Fukuda, MM; Green, JA; Ittiverakul, M; Krudsood, S; Miller, RS; Mohamed, K; Noedl, H; Ohrt, C; Sriwichai, S; Warrasak, S	1
Bancone, G; Chu, CS; Jittamala, P; Taylor, WRJ; Watson, J; White, NJ	1
Bancone, G; Bansil, P; Chu, CS; Domingo, GJ; Gornsawun, G; Nosten, F; Pal, S; Porn, P	1
Hwang, J; Tan, KR	1
Euswas, A; Fukuda, MM; Ittiverakul, M; Krudsood, S; Miller, RS; Ohrt, C; Warrasak, S	1
Baird, JK	1
Berman, J; Brown, T; Dow, G; Toovey, S	1
White, NJ	1
Abdissa, A; Abebe, C; Angus, B; Batista Pereira, D; Beck, HP; Brand, F; Breton, JJ; Brito, MAM; Buathong, N; Casapía, M; Chuquiyauri, R; Clover, DD; Costa, MRF; Diro, E; Duparc, S; Espino, FEJ; Fletcher, K; Getie, S; Green, JA; Hardaker, E; Jones, SW; Kellam, LM; Kleim, JP; Koh, GCKW; Krudsood, S; Lacerda, MVG; Llanos-Cuentas, A; Lon, C; Mia, RZ; Mohamed, K; Mohammed, R; Monteiro, WM; Noedl, H; Rousell, VM; Saunders, DL; Tada, MS; Ugwuegbulam, CO; Val, F; Wubie, KM; Yilma, D; Zeynudin, A	1
Angus, B; Aruachan, S; Bancone, G; Breton, JJ; Brito, MAM; Casapía, M; Chu, CS; Chuquiyauri, R; Clover, DD; Costa, MRF; Craig, G; Duparc, S; Green, JA; Hardaker, E; Hien, TT; Jones, SW; Kendall, L; Koh, GCKW; Lacerda, MVG; Llanos-Cuentas, A; Mohamed, K; Monteiro, WM; Namaik-Larp, C; Nguyen, CH; Nosten, FH; Papwijitsil, R; Rousell, VM; Val, F; Vélez, ID; Villegas, MF; Wilches, VM	1
McCarthy, S; Quinn, JC	1
Taylor, AR; Watson, JA	1
Duparc, S; Green, JA; Koh, GCKW	1
Bifani, P; Chuenchob, V; Dembele, L; Diagana, TT; Flannery, EL; Gupta, DK; Ishino, T; Kangwanrangsan, N; Kappe, SH; Kocken, CH; Mikolajczak, S; Roma, G; Sattabongkot, J; Vaughan, AM; Voorberg-van der Wel, A; Yip, A	1
Chen, V; Daily, JP	1
Arthur, P; Carter, N; Chuenchom, N; Duparc, S; Green, JA; Gupta, SK; Kellam, L; Kleim, JP; Kochar, SK; Krudsood, S; Lacerda, MV; Llanos-Cuentas, A; Möhrle, JJ; Rueangweerayut, R; Ugwuegbulam, C	1
Nosten, F; Price, RN	1
Dow, GS; McCarthy, WF; Reid, M; Shanks, GD; Smith, B; Tang, D	1
Burrows, JN; Campo, B; Vandal, O; Wesche, DL	1
Fernando, SD; Rajapakse, S; Rodrigo, C	1
Goyal, N; Green, JA; Tenero, D	1
Beck, HP; Carter, N; Duparc, S; Green, JA; Koh, G; Krudsood, S; Lacerda, MV; Llanos-Cuentas, A; Osorio, L; Rubio, JP; Rueangweerayut, R; Wampfler, R	1
Beaumont, C; Carter, N; Duparc, S; Green, JA; Koh, GC; Krudsood, S; Llanos-Cuentas, A; Rubio, JP; Rueangweerayut, R; St Jean, PL; Taylor, M; Xue, Z	1
Abay, SM; Ebstie, YA; Ejigu, DA; Tadesse, WT	1
Bouhired, S; Duparc, S; Goyal, N; Green, JA; Hussaini, A; Jones, SW; Koh, GC; Kostov, I; Mohamed, K; Taylor, M; Wolstenholm, A	1
Edstein, MD; Elmes, NJ; Kitchener, SJ; Kocisko, DA; Nasveld, PE	1
Peters, W; Robinson, BL; Stewart, LB	1
Coleman, RE; Eikarat, N; Kittayapong, P; Ponsa, N; Sattabongkot, J	1
Brewer, TG; Cherdchu, C; Eamsila, C; Edstein, MD; Jarasrumgsichol, P; Khaewsathien, P; Rieckmann, KH; Sangkharomya, S; Sasiprapha, T; Supakalin, P; Tang, DB; Walsh, DS	1
Brewer, TG; Heppner, DG; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Siriyanonda, D; Tang, DB; Walsh, DS; Wilairatana, P	1
Kitchener, S; Nasveld, P	1
Edstein, MD; Gatton, ML; Kitchener, SJ; Kocisko, DA; Nasveld, PE; Rieckmann, KH	1
Edstein, MD; Kitchener, S; Nasveld, P	1
Crockett, M; Kain, KC	1
Cooper, RD; Kyle, DE; Nuzum, EO; Obaldia, N; Rieckmann, KH; Rossan, RN; Shanks, GD	1
Braitman, DJ; Brewer, TG; Brueckner, RP; Chokejindachai, W; Heppner, DG; Horton, J; Kyle, DE; Looareesuwan, S; Milhous, WK; Schuster, BG; Tang, DB; Viriyavejakul, P; Walsh, DS; Wilairatana, P	1
Eamsila, C; Edstein, MD; Kitchener, S; Nasveld, PE; Rieckmann, KH; Sasiprapha, T; Walsh, DS	1
Brewer, TG; Charles, BG; Eamsila, C; Edstein, MD; Kocisko, DA; Walsh, DS	1

Reviews

14 review(s) available for tafenoquine and Plasmodium vivax Malaria

Article	Year
Tafenoquine for the treatment of Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:7 Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence	2022
Tafenoquine for The Indian journal of medical research, 2021, Volume: 154, Issue:6 Topics: Aminoquinolines; Antimalarials; Female; Humans; Malaria, Vivax; Plasmodium vivax; Pregnancy; Primaquine; Recurrence	2021
Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review. Malaria journal, 2020, Mar-14, Volume: 19, Issue:1 Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Nervous System Diseases; Plasmodium vivax; Secondary Prevention	2020
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. The Cochrane database of systematic reviews, 2020, 09-06, Volume: 9 Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Drug Administration Schedule; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Parasitemia; Placebos; Primaquine; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention	2020
Tafenoquine: a toxicity overview. Expert opinion on drug safety, 2021, Volume: 20, Issue:3 Topics: Adult; Aminoquinolines; Animals; Antimalarials; Dose-Response Relationship, Drug; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Mental Disorders	2021
The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg). Malaria journal, 2017, 05-19, Volume: 16, Issue:1 Topics: Aminoquinolines; Animals; Antimalarials; Half-Life; Humans; Malaria, Falciparum; Malaria, Vivax; Plasmodium falciparum; Plasmodium vivax; Schizonts	2017
Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines. Malaria journal, 2018, Nov-06, Volume: 17, Issue:1 Topics: Aminoquinolines; Animals; Antimalarials; Humans; Macaca mulatta; Malaria, Vivax; Primaquine	2018
Tafenoquine: the new kid on the block. Current opinion in infectious diseases, 2019, Volume: 32, Issue:5 Topics: Aminoquinolines; Antimalarials; Chemoprevention; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Malaria, Vivax	2019
Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax. Pathogens and global health, 2015, Volume: 109, Issue:3 Topics: Aminoquinolines; Antimalarials; Chemical and Drug Induced Liver Injury; Disease Eradication; Drug Discovery; Humans; Liver; Malaria, Vivax; Plasmodium vivax; Recurrence; Sporozoites	2015
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. The Cochrane database of systematic reviews, 2015, Apr-29, Issue:4 Topics: Adult; Aminoquinolines; Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Primaquine; Primary Prevention; Randomized Controlled Trials as Topic; Recurrence	2015
Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug design, development and therapy, 2016, Volume: 10 Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax	2016
Primaquine in vivax malaria: an update and review on management issues. Malaria journal, 2011, Dec-12, Volume: 10 Topics: Aminoquinolines; Antimalarials; Artemisinins; Chloroquine; Clinical Trials as Topic; Drug Resistance; Glycogen Storage Disease Type I; Hemolysis; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine	2011
Tafenoquine: a promising new antimalarial agent. Expert opinion on investigational drugs, 2007, Volume: 16, Issue:5 Topics: Aminoquinolines; Animals; Antimalarials; Humans; Malaria, Falciparum; Malaria, Vivax; Recurrence; Treatment Outcome	2007
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force. Medecine tropicale : revue du Corps de sante colonial, 2001, Volume: 61, Issue:1 Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Military Personnel; Primaquine	2001

Trials

19 trial(s) available for tafenoquine and Plasmodium vivax Malaria

Article	Year
Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial. The Lancet. Child & adolescent health, 2022, Volume: 6, Issue:2 Topics: Adolescent; Aminoquinolines; Antimalarials; Area Under Curve; Child; Child, Preschool; Chloroquine; Female; Humans; Malaria, Vivax; Male; Recurrence; Secondary Prevention; Tablets	2022
Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. The Lancet. Infectious diseases, 2023, Volume: 23, Issue:10 Topics: Antimalarials; Artemisinins; Chloroquine; Drug Therapy, Combination; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine; Quinolines	2023
Provider and household costs of Bulletin of the World Health Organization, 2019, Dec-01, Volume: 97, Issue:12 Topics: Absenteeism; Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Cost of Illness; Cost-Benefit Analysis; Female; Financing, Personal; Global Health; Health Expenditures; Health Services; Humans; Malaria, Vivax; Male; Middle Aged; Models, Economic; Transportation; Young Adult	2019
A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria. PloS one, 2017, Volume: 12, Issue:11 Topics: Adult; Aminoquinolines; Animals; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fever; Humans; Malaria, Vivax; Male; Parasites; Plasmodium vivax; Treatment Outcome; Young Adult	2017
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. International ophthalmology, 2019, Volume: 39, Issue:8 Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method; Eye Infections, Parasitic; Female; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Primaquine; Retina; Retrospective Studies; Slit Lamp Microscopy; Time Factors; Treatment Outcome; Young Adult	2019
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3 Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Glucosephosphate Dehydrogenase; Hemoglobins; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Malaria, Vivax; Male; Parasitemia; Plasmodium vivax; Primaquine; Secondary Prevention	2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3 Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Humans; Kaplan-Meier Estimate; Malaria, Vivax; Male; Parasitemia; Plasmodium vivax; Primaquine; Prospective Studies; Secondary Prevention	2019
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922 Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; India; Malaria, Vivax; Male; Middle Aged; Peru; Primaquine; Secondary Prevention; Thailand; Treatment Outcome; Young Adult	2014
Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax Malaria. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:10 Topics: Adult; Aminoquinolines; Antimalarials; Double-Blind Method; Female; Humans; Logistic Models; Malaria, Vivax; Male; Plasmodium vivax; Young Adult	2015
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping. The Journal of infectious diseases, 2016, Mar-01, Volume: 213, Issue:5 Topics: Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; Genotype; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Secondary Prevention	2016
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malaria journal, 2016, Feb-18, Volume: 15 Topics: Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Primaquine; Treatment Outcome	2016
Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:12 Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Artemisinins; Drug Interactions; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Half-Life; Healthy Volunteers; Humans; Lumefantrine; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Quinolines; Young Adult	2016
The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, Volume: 102, Issue:11 Topics: Adult; Aminoquinolines; Animals; Antimalarials; Australia; Dose-Response Relationship, Drug; Female; Humans; Malaria, Vivax; Male; Military Personnel; Plasmodium vivax; Primaquine; Statistics as Topic; Young Adult	2008
Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria. The Journal of infectious diseases, 2004, Oct-15, Volume: 190, Issue:8 Topics: Administration, Oral; Aminoquinolines; Animals; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Multiple; Follow-Up Studies; Humans; Malaria, Falciparum; Malaria, Vivax; Military Personnel; Plasmodium falciparum; Thailand; Treatment Outcome	2004
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Oct-15, Volume: 39, Issue:8 Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Malaria, Vivax; Male; Methemoglobin; Middle Aged; Primaquine; Risk; Secondary Prevention; Time Factors	2004
Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, Volume: 101, Issue:3 Topics: Adult; Aminoquinolines; Antimalarials; Drug Administration Schedule; Drug Monitoring; Female; Gastrointestinal Diseases; Humans; Malaria, Vivax; Male; Nausea; Sex Characteristics	2007
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. The Journal of infectious diseases, 1999, Volume: 180, Issue:4 Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Malaria, Vivax; Male; Prospective Studies; Recurrence; Thailand	1999
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force. Medecine tropicale : revue du Corps de sante colonial, 2001, Volume: 61, Issue:1 Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Military Personnel; Primaquine	2001
Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. British journal of clinical pharmacology, 2001, Volume: 52, Issue:6 Topics: Administration, Oral; Adult; Aminoquinolines; Antimalarials; Artemisinins; Artesunate; Computer Simulation; Doxycycline; Half-Life; Humans; Malaria, Vivax; Male; Metabolic Clearance Rate; Middle Aged; Military Personnel; Models, Biological; Observer Variation; Sesquiterpenes; Thailand	2001

Other Studies

28 other study(ies) available for tafenoquine and Plasmodium vivax Malaria

Article	Year
Tafenoquine for the prevention of Plasmodium vivax malaria relapse. The Lancet. Microbe, 2021, Volume: 2, Issue:5 Topics: Aminoquinolines; Humans; Malaria, Vivax; Primaquine; Recurrence	2021
Cost-Benefit Analysis of Tafenoquine for Radical Cure of Journal of Korean medical science, 2022, Jul-11, Volume: 37, Issue:27 Topics: Aminoquinolines; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Vivax; Primaquine; Recurrence	2022
Tafenoquine and artemisinin-based combination therapy for vivax malaria: end of the road or just the beginning? The Lancet. Infectious diseases, 2023, Volume: 23, Issue:10 Topics: Aminoquinolines; Antimalarials; Artemisinins; Humans; Malaria, Vivax; Plasmodium vivax	2023
Killing of Plasmodium vivax by Primaquine and Tafenoquine. Trends in parasitology, 2019, Volume: 35, Issue:11 Topics: Aminoquinolines; Antimalarials; Humans; Hydrogen Peroxide; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence	2019
Cost-utility of tafenoquine vs. primaquine for the radical cure (prevention of relapse) of Journal of chemotherapy (Florence, Italy), 2020, Volume: 32, Issue:1 Topics: Aminoquinolines; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Vivax; Markov Chains; Monte Carlo Method; Primaquine; Recurrence; Serbia	2020
Tafenoquine: A Step toward Malaria Elimination. Biochemistry, 2020, 03-03, Volume: 59, Issue:8 Topics: Aminoquinolines; Anemia, Hemolytic; Animals; Antimalarials; Cytochrome P-450 CYP2D6; Gene Knockdown Techniques; Glucosephosphate Dehydrogenase Deficiency; Haplorhini; Humans; Malaria, Vivax; Methemoglobinemia; Mice; Plasmodium cynomolgi; Plasmodium vivax; Zebrafish	2020
Cost-Effectiveness Analysis of Sex-Stratified The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:1 Topics: Adult; Afghanistan; Aminoquinolines; Anemia, Hemolytic; Antimalarials; Chloroquine; Cost-Benefit Analysis; Ethiopia; Female; Glucosephosphate Dehydrogenase Deficiency; Hemizygote; Heterozygote; Homozygote; Humans; Indonesia; Malaria, Vivax; Male; Mass Screening; Medication Adherence; Plasmodium vivax; Primaquine; Quality-Adjusted Life Years; Recurrence; Sex Factors; Vietnam	2020
Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria. Pharmacogenetics and genomics, 2020, Volume: 30, Issue:7 Topics: Adult; Aminoquinolines; Antimalarials; Chromosomes, Human, Pair 12; Clinical Trials as Topic; Female; Genome-Wide Association Study; Humans; Malaria, Vivax; Male; Middle Aged; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Retrospective Studies; Treatment Outcome; Young Adult	2020
Letter to the editor: G6PD deficiency in the Tafenoquine era. MSMR, 2020, Volume: 27, Issue:6 Topics: Aminoquinolines; Antimalarials; Contraindications, Drug; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Male; Mass Screening; Military Personnel; Plasmodium vivax; Population Surveillance; Prevalence; United States	2020
Towards one standard treatment for uncomplicated Plasmodium falciparum and Plasmodium vivax malaria: Perspectives from and for the Peruvian Amazon. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 105 Topics: Adult; Aminoquinolines; Artemisinins; Female; Humans; Malaria, Falciparum; Malaria, Vivax; Peru; Plasmodium falciparum; Plasmodium vivax; Prevalence; Primaquine; Reference Standards	2021
Relapses of BMJ global health, 2021, Volume: 6, Issue:2 Topics: Aminoquinolines; Disease Eradication; Humans; India; Malaria, Vivax; Recurrence	2021
Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study. PLoS medicine, 2021, Volume: 18, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antimalarials; Brazil; Child; Child, Preschool; Disease Eradication; Female; Humans; Infant; Infant, Newborn; Malaria, Vivax; Male; Middle Aged; Models, Theoretical; Plasmodium vivax; Prevalence; Secondary Prevention; Young Adult	2021
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. PLoS neglected tropical diseases, 2018, Volume: 12, Issue:4 Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Heterozygote; Humans; Lactation; Malaria, Vivax; Male; Plasmodium vivax; Pregnancy; Primaquine; Young Adult	2018
Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood. PloS one, 2018, Volume: 13, Issue:5 Topics: Adult; Aminoquinolines; Antimalarials; Area Under Curve; Biosensing Techniques; Clinical Enzyme Tests; Endemic Diseases; Ethnicity; Female; Genotype; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hemoglobinometry; Humans; Malaria, Vivax; Male; Methemoglobinemia; Myanmar; Point-of-Care Systems; Pregnancy; Pregnancy Complications, Hematologic; Primaquine; ROC Curve; Spectrophotometry, Ultraviolet	2018
Tafenoquine receives regulatory approval in USA for prophylaxis of malaria and radical cure of Plasmodium vivax. Journal of travel medicine, 2018, 01-01, Volume: 25, Issue:1 Topics: Aminoquinolines; Antimalarials; Drug Approval; Humans; Malaria, Vivax; Plasmodium vivax; Secondary Prevention; United States; United States Food and Drug Administration	2018
Tafenoquine for travelers' malaria: evidence, rationale and recommendations. Journal of travel medicine, 2018, 01-01, Volume: 25, Issue:1 Topics: Adult; Aminoquinolines; Antimalarials; Dose-Response Relationship, Drug; Female; Humans; Infection Control; Malaria; Malaria, Vivax; Male; Travel; United States; United States Food and Drug Administration	2018
Tafenoquine - A Radical Improvement? The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3 Topics: Aminoquinolines; Humans; Malaria, Vivax; Primaquine; Recurrence	2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. The New England journal of medicine, 2019, 05-09, Volume: 380, Issue:19 Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence	2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. The New England journal of medicine, 2019, 05-09, Volume: 380, Issue:19 Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence	2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply. The New England journal of medicine, 2019, 05-09, Volume: 380, Issue:19 Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence	2019
The eLife, 2019, 05-16, Volume: 8 Topics: Aminoquinolines; Animals; Antimalarials; Biomarkers; Biomarkers, Pharmacological; Hepatocytes; Host-Parasite Interactions; Humans; Liver; Macaca mulatta; Malaria, Vivax; Plasmodium cynomolgi; Plasmodium vivax; Protozoan Proteins; Sporozoites; Transcriptome	2019
Single-dose radical cure of Plasmodium vivax: a step closer. Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922 Topics: Aminoquinolines; Antimalarials; Chloroquine; Female; Humans; Malaria, Vivax; Male	2014
A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area. Malaria journal, 2014, Feb-06, Volume: 13 Topics: Aminoquinolines; Antimalarials; Australia; Chemoprevention; Endemic Diseases; Humans; Incidence; Malaria, Falciparum; Malaria, Vivax; Mefloquine; Military Personnel; Retrospective Studies; Timor-Leste; Travel; Treatment Outcome; United States	2014
The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines. Annals of tropical medicine and parasitology, 2003, Volume: 97, Issue:3 Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Drug Therapy, Combination; Malaria; Malaria, Falciparum; Malaria, Vivax; Mefloquine; Mice; Plasmodium berghei; Plasmodium chabaudi; Plasmodium yoelii; Primaquine; Time Factors	2003
Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. The American journal of tropical medicine and hygiene, 2003, Volume: 69, Issue:5 Topics: Aminoquinolines; Animals; Anopheles; Antimalarials; Artemisinins; Dose-Response Relationship, Drug; Humans; Insect Vectors; Malaria, Vivax; Mice; Parasitic Sensitivity Tests; Plasmodium vivax; Primaquine; Sesquiterpenes	2003
Treatment of acute vivax malaria with tafenoquine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, Volume: 99, Issue:1 Topics: Acute Disease; Administration, Oral; Adult; Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Male; Parasitemia; Treatment Outcome	2005
Tafenoquine for the treatment of recurrent Plasmodium vivax malaria. The American journal of tropical medicine and hygiene, 2007, Volume: 76, Issue:3 Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Humans; Malaria, Vivax; Recurrence	2007
WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. The American journal of tropical medicine and hygiene, 1997, Volume: 56, Issue:5 Topics: Aminoquinolines; Animals; Antimalarials; Aotus trivirgatus; Chloroquine; Drug Resistance; Drug Therapy, Combination; Malaria, Vivax; Parasitemia	1997